

Pharmaceuticals and Biotechnology

Istanbul, 23 September 2014

- | | |
|--------------------|--|
| 09.30-10.00 | Registration, sandwiches and coffee/tea |
| 10.00-10.15 | Official welcome

Serdar Sözeri – Head of IEIS R&D Working Group

Fraunhofer Group for Life Sciences |
| 10.15-10.45 | Introduction of the Fraunhofer-Gesellschaft and the Fraunhofer Group for Life Sciences

Dr. Claus-Dieter Kroggel, Head of Central Office, Fraunhofer Group for Life Sciences

Prof. Friedemann Horn, Fraunhofer Institute for Cell Therapy and Immunology IZI The Fraunhofer-Group for Life Sciences |
| 10.45-11.00 | R&D objectives of the Turkish pharmaceutical industry and IEIS efforts for enhancing the industry's R&D capacity

Omer Hulki Ocak - Member of IEIS R&D Working Group |
| 11.00-11.10 | Q&A |
| 11.10-11.30 | Coffee break |
| 11.30-11.45 | Cell line development for production of biopharmaceutical and biosimilar APIs

Dr. Steffen Rupp, Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB |
| 11.45-12.00 | Bioprocess development and early stage GMP manufacturing of biopharmaceutical and biosimilar APIs

Dr. Holger Ziehr, Fraunhofer Institute for Toxicology and Experimental Medicine ITEM |
| 12.00-12.10 | Q&A |
| 12.10-12.25 | R & D Contracts - an insight into Fraunhofer's way of negotiating |

Dr. Stefanie Edlbauer, Fraunhofer Headquarters, Attorney at Law in the Department Research and Development Contracts

12.25-12.35

Q&A

12.40-14.00

Lunch

14.00-14.20

Development of a universal modular system for the production of virus-like particles: Novel platform technology for drug delivery and vaccine production

Dr. Susanne Bailer, Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB

14.20-14.25

Q&A

14.25-14.45

The proof-of-concept center for early-phase clinical development and medical devices

Prof. Dr. Norbert Krug, Fraunhofer Institute for Toxicology and Experimental Medicine ITEM Clinical Research Center Hannover:

14.45-14.55

Q&A

14.55-15.15

Coffee break

15.15-15.55

Next generation diagnostics

Dr. Kai Sohn, Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB

Developing New Biomarkers for Personalized Medicine: The RIBOLUTION Consortium

Prof. Friedemann Horn, Fraunhofer Institute for Cell Therapy and Immunology IZI

15.55-16.05

Q&A